Therapeutic Response

CD22 + status confers therapeutic sensitivity to Inotuzumab ozogamicin in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Besponsa (inotuzumab ozogamicin) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to inotuzumab ozogamicin for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
Besponsa (inotuzumab ozogamicin) [product monograph]. HC. Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).